Assembly Biosciences (ASMB) EBIT Margin (2017 - 2026)
Assembly Biosciences (ASMB) recorded quarterly EBIT Margin of 138.44% in Q1 2026, down 291.94% quarter-over-quarter from 72.13% in Q4 2025, and down 3290.0% on a YoY basis from 4.34% in Q1 2025.
Assembly Biosciences (ASMB) EBIT Margin (2017 - 2026) Analysis & Trends
Assembly Biosciences' EBIT Margin history runs 9 years deep, the most recent figure standing at 138.44% for Q1 2026.
- In Q1 2026, EBIT Margin fell 3290.0% year-over-year to 138.44%; the TTM figure through Mar 2026 stood at 3.82% (up 13499.0% YoY), while the FY2025 annual figure was 1.78%, up 15748.0% from the prior year.
- EBIT Margin was 138.44% for Q1 2026 at Assembly Biosciences, down from 72.13% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 72.13% in Q4 2025 to a low of 185.46% in Q1 2024.
- Historically, EBIT Margin has averaged 120.85% across 4 years, with a median of 140.72% in 2026.
- The sharpest annual moves came in 2025 and 2026: EBIT Margin jumped 22887 bps in 2025, then slumped 3290 bps in 2026.
- A 4-year view of EBIT Margin shows it stood at 175.22% in 2023, then rose by 11 bps to 156.75% in 2024, then soared by 146 bps to 72.13% in 2025, then sank by 292 bps to 138.44% in 2026.
- The last three EBIT Margin figures came in at 138.44% (Q1 2026), 72.13% (Q4 2025), and 100.87% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Assembly Biosciences | 418.96 Mn | 192.36 Mn | - | -138.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -138.44% |
| Dec 31, 2025 | 72.13% |
| Sep 30, 2025 | -100.87% |
| Jun 30, 2025 | -115.24% |
| Mar 31, 2025 | -105.54% |
| Dec 31, 2024 | -156.75% |
| Sep 30, 2024 | -160.06% |
| Jun 30, 2024 | -143.01% |
| Mar 31, 2024 | -185.46% |
| Dec 31, 2023 | -175.22% |
| Sep 30, 2021 | -301.81% |
| Dec 31, 2020 | -3,822.76% |
| Sep 30, 2020 | -11.61% |
| Jun 30, 2020 | 16.71% |
| Mar 31, 2020 | -678.61% |
| Dec 31, 2019 | -601.72% |
| Sep 30, 2019 | -614.35% |
| Jun 30, 2019 | -639.61% |
| Mar 31, 2019 | -729.37% |
| Dec 31, 2018 | -704.74% |